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Abstract 
Objective: The objective of this selective EBM review is to determine whether or not high dose 
intramuscular alefacept is a more effective and a safe treatment option in visibly reducing the 
severity of chronic plaque psoriasis in men and women 16 years and older compared to standard 
IV and IM treatment forms. 
 
Study Design: Review of three dichotomous data, English language, and primary randomized 
controlled trials published 2003 – 2008. 
 
Data Sources: Randomized, controlled clinical trials comparing alefacept to a control 
group were found using PubMed database. 
 
Outcome Measured: Disease improvement and the adverse effect of headache. Disease 
improvement was measured using the Physician’s Global Assessment (0=clear, 5=severe) 
and the Psoriasis Area and Severity Index (0 = no disease, 72 = maximal disease). 
Numbers needed to treat were calculated for efficacy and numbers needed to harm was 
calculated to determine safety. 
 
Results:  The efficacy, based  on NNT, of high dose alefacept, 30 mg IM was calculated based 
on Cafardi et al’s trial to be 8 compared to Krueger’s trial of 4, and Ortonne’s 5.  NNH for 
headaches were calculated to be -8 for Cafardi et al, -100 from Krueger, and 34 from Ortonne. 
 
Conclusion:  After researching the three randomized control trials, alefacept 30 mg IM weekly 
for 12 weeks does not provide more effective results when treating chronic plaque psoriasis 
compared to standard doses of 7.5 mg IV or 15 mg IM weekly.  Headaches were also seen more 
commonly as an adverse effect with high dose alefacept.  As a result, standard doses of the 
biologic agent should be continued to be used to treat chronic plaque psoriasis that does not 
respond to other interventions and more studies must be further performed with alefacept 30 mg 
IM weekly. 
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Introduction:   
“Psoriasis is hyperproliferation of epidermal keratinocytes combined with inflammation 
of the epidermis and dermis. It affects about 1 to 5% of the population worldwide; light-skinned 
people are at greater risk. Peak onset is roughly bimodal, most often at ages 16 to 22 and at ages 
57 to 60, but the disorder can occur at any age.1”  The dermatologic disease is chronic and 
currently does not have a cure.  The most common type is plaque psoriasis frequently found to 
appear on the extensor surfaces of body1.  An estimated 2.5% Caucasians and 1.5% African 
Americans in the United States are affected.2  The estimated medical cost is 11.25 billion a year 
for United States to treat this condition.2  Approximately 60 percent of psoriasis patients missed 
an average of 26 days of work a year due to their illness2.   
The cause of psoriasis is still unknown but there are suggestions.  Currently, the disease 
is thought to be autoimmune with T cells being greatly involved in the rapid cell turnover rate.  
The unknown mechanism results in cells attacking the keratinocytes and causing an excessive 
growth rate.  As a result, what is seen on the skin with plaque psoriasis is a silvery scale with an 
erythematous base that can be pruritic1. 
There is an extensive list of treatments available to treat psoriasis and its subtypes.  “Mild 
plaque psoriasis can be treated with emollients, keratolytics, tar, topical corticosteroids, vitamin 
D3 analogs, or anthralin alone or in combination. Exposure to sunlight is beneficial, but sunburn 
can induce exacerbations.  Moderate to severe plaque psoriasis should be treated with topical 
agents and either phototherapy or systemic agents. Immunosuppressants are used for quick, 
short-term control (eg, in allowing a break from other modalities) and for the most severe 
disease. Immunomodulatory agents (biologics) are used for moderate to severe disease 
unresponsive to other agents.1” 
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 This paper researches Alefacept, a biological agent that is fairly new and has been used 
both intramuscularly and intravenously to treat plaque psoriasis.  Standard doses consist of 15 
mg intramuscular (IM) and 7.5 mg intravenous (IV).  30 mg IM is a high dose that is thought to 
have more desired effects than the standard doses. 
Objective:   
The objective of this selective EBM review is to determine whether or not high dose 
intramuscular alefacept is a more effective and a safe treatment option in visibly reducing the 
severity of chronic plaque psoriasis in men and women 16 years and older compared to standard 
IV and IM treatment forms. 
Methods:   
Each study was dichotomous data involving men and women of various ages who were 
diagnosed with chronic plaque psoriasis for at least twelve months prior to the study.  The 
biological agent alefecept was administered for 12 weeks in either 30 mg IM, 15 mg IM , or 7.5 
mg IV bolus and compared with the control group.  Each patient’s severity was determined by 
the Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA).  PASI 
determines the severity with a scale ranging from 0 – 72.  72 means the severity is most severe 
and includes the entire body surface area (BSA).  PGA measures how clear a person’s skin is.  
The scale ranges from 0 – 5 with 5 being severe psoriasis.  The articles researched included two 
randomized double blind parallel group studies and one single center randomized open label 
study. 
Cafardi et al compared 30 mg IM for 12 weeks to 30 mg IM for 6 weeks followed by 15 
mg IM for 6 weeks.4  The safety, efficacy, and tolerability were assessed.  Krueger compared 12 
weeks of 7.5 mg IV over 30 seconds to a placebo group5.  Two courses were preformed making 
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the study 24 weeks long.  This paper researches only one course which included weeks 1 – 12.  
Ortonne compares 15 mg IM to a placebo group.6  Ortonne initial time frame was 24 weeks but 
this paper researches only the initial 12 weeks.  Ortonne and Krueger like Cafardi et al assessed 
the safety, efficacy, and tolerability. 
Words used when searching were chronic plaque psoriasis, alefecept, and efficacy.  Each 
article was published, peer reviewed, and printed in English   PubMed database was used to 
locate the three articles.  Articles were selected based on relevance and patient oriented evidence 
that matters.  Inclusion criteria had to meet at least 16 y.o with chronic stable plaque psoriasis, 
good health, with normal CD4+ counts, and BSA of at least 10% effected.  Exclusions included 
other forms of psoriasis other than plaque, serious systemic infections within 3 months, HIV 
positive, hepatitis, malignancies, treatment with phototherapy, steroids, etc within 4 weeks.  
Table 1 below provides specific inclusion and exclusion criteria for each article.  P-value, 
absolute benefit increase (ABI), relative benefit increase (RBI), numbers needed to treat (NNT), 
and absolute risk increase (ARI), relative risk increase (RRI), and numbers needed to harm 
(NNH) were evaluated.  These values were specifically looked at to determine which 
intervention provided the most effective treatment with the least adverse effects.  
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Demographics and Characteristics of included studies (Table 1)  
Study Type # 
patient
s 
Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Intervention 
Cafardi 
2008 
RCT 16 32-60 Men and 
women at 
least 19 y.o 
with a hx or 
chronic 
plaque 
psoriasis 
requiring 
treatment. 
Were in good 
health and 
normal CD4 
counts. 
Known hepatitis, 
TB, HIV, CD4 
<380, hx of 
malignancy, 
known 
immunosuppressi
on other than 
DM, local infx 
within 3 months.  
Other txt within 
28 days, pregnant, 
planning to 
become pregnant, 
nursing mothers. 
2 30 mg IM 
once a week 
Alefecept 
for 12 wks. 
Kruger 
2003 
RCT 183 > or 
equal 
to 16 
At least 16 
y.o. chronic 
stable plaque 
psoriasis more 
than 12 
months with 
BSA 10%, 
CD4 wnl,  
Any other form of 
psoriasis, local or 
systemic infx 
within 3 months, 
HIV, hepatitis, 
malignancy, other 
forms of systemic 
tx within 4 weeks 
or topical within 
2 weeks except 
on scalp, palms, 
groin, arm fold 
region or soles.  
15 7.5 mg IV 
bolus for 30 
seconds 
once a week 
Alefecept 
for 12 
weeks. 
Ortonne 
2003 
RCT 166 18-84 At least 18 
y.o. with 
chronic stable 
plaque 
psoriasis for 
at least 12 
months, BSA 
of at least 
10% and CD4 
count wnl. 
Other forms of 
psoriasis, HIV, 
hepatitis, 
systemic infx 
within 3 months, 
malignancy, 
systemic tx within 
4 weeks or topical 
tx within 2 weeks 
except for scalp. 
groin, arm folds, 
palms, and soles. 
N/A 15 mg 
Alefecept 
IM once a 
week for 12 
weeks. 
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Results:  
Cafardi et al researched a 12 week course of 30 mg alefacept IM and compared the 
results to a 6 week course of 30 mg IM followed by 15 mg for an additional 6 weeks.  Fifty 
percent of the patients responded with a PASI reduction of 50 – 75% with the 30 mg dose for 12 
weeks compared to a 37.5% PASI reduction in the control group.  Eight patients were initially 
given a PGA score of 3 and after intervention 3 continued to have a PGA score of 3.  This is 
compared to the control in which 5 patients initially had a PGA score of 3 and after treatment 2 
patients continued to have a score of 3.  The ABI was calculated to be 0.125 and the RBI was    
0.333.  Numbers needed to treat was calculated to be 8.  Results are displayed in Table 2. 
Krueger’s study involved a two course consisting of a total of 24 weeks.  This paper 
researches only course 1, the initial 12 weeks of 7.5 mg IV alefacept compared to IV placebo.  
56% of the patients in the experiment group saw over a 50% PASI reduction compared to a 23% 
reduction in the placebo group.  The results were significant with a p-value <0.001.  Course 1 
PGA score of clear or almost clear was seen in 23% of course 1 experiment patients compared to 
6% of placebo group.  The ABI was calculated to 0.320 and the RBI was 1.33.  Numbers needed 
to treat was found to be 4. 
Ortonne’s study includes 12 weeks of dosing and 12 weeks of follow up.  This paper 
researches the initial 12 weeks of dosing.  15 mg IM alefacept was compared to a placebo group.  
57% responded to a greater than 50% PASI reduction compared to the 35% in the control. The 
results were significant, p-value 0.002.  The PGA of clear or almost clear was seen 22% of the 
experiment group compared to 8% in the control.  The ABI was calculated to be 0.220 and RBI 
was  0.630.  The NNT was determined to be 5. 
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Table 2:  Results of therapeutic intervention PASI 
Study Experiment Control P-value ABI RBI NNT 
Cafardi 4/8 
50.0% 
3/8 
38.0% 
N/A 0.125 0.333 8 
Krueger 205/367 
56.0% 
43/186 
23.0% 
<0.001 0.320 1.33 4 
Ortonne 94/166 
57.0% 
58/168 
35.0% 
0.002 0.220 0.630 5 
 
 
Study Experiment Control P-value ABI RBI NNT 
Cafardi 0.25 0.25 0.01 0 0 0 
Krueger 0.23 0.06 N/A 0.17 2.83 6 
Ortonne 0.22 0.08 <0.001 0.14 1.75 8 
 
Table 4 provides the results for numbers needed to harm.  Headache was chosen because 
among the three trials the occurrence was common.  Cafardi et al NNH was 8, for Krueger’s 
study 100 was calculated, and Ortonne’s study found -34 to be calculated. 
Table 4:  Results of adverse effects headaches. 
Study Experiment Control P-value ARI RRI NNH 
Cafardi et al 2/8 
25.0% 
3/8 
38.0% 
N/A -0.130 -0.330 -8 
Krueger 30/154 
19.0% 
38/186 
20.0% 
N/A -0.010 -0.0500 -100 
Ortonne 30/166 
18.0% 
26/168 
15.0% 
N/A 0.030 0.200 34 
 
Discussion: 
 The results of the three randomized control trials suggests high dose alefacept weekly for 
12 weeks was not as effective in treating chronic plaque psoriasis as compared to standard doses.  
Standard doses consisting of 15 mg IM and 7.5 mg IV had similar efficacy results with 
intravenous route allowing less patients needed to be treated to provide a PASI reduction of at 
least 50%. 
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Table 3: Result of therapeutic intervention PGA 
 Analyzing the common adverse effect of headache in each of the control trials found 
intravenous administration of 7.5 mg alefacept provided the least amount of headaches.  One 
hundred patients would have to be treated before one patient complained of the headaches.  High 
dose alefacept was found to cause headaches the most.  
The inclusion and exclusion criteria between the three studies were similar.  Differences 
between trials included, Krueger allowing patients as young as sixteen while Cafardi et all set a 
minimum of nineteen.  The number of patients 16 years old was not discussed in Kueger’s 
article.  Another difference was Kueger and Ortonne set a boundary that subjects had to have 
stable plaque psoriasis with a diagnosis of at least 12 months while Cafardi et al only said the 
subjects had to have a history of chronic plaque psoriasis.  Krueger and Ortonne had clear 
placebo groups in their study while Cafardi et al had a control group that consisted of two 
distinct treatments over the same time period.  A major difference between these studies is the 
sample size.  Cafardi et al had a sample size of 16 compared to 183 in Krueger’s study and 166 
in Ortonne’s study. 
Conclusion: 
 According to this EBM review, 30 mg alefacept IM once weekly does not provide more 
efficacy and safety when treating chronic plaque psoriasis as compared to standard doses.  
Greater number of patients were needed to treat to provide effective results and less patients 
were needed to cause adverse effects. 
 For the future, suggestions to improve studies looking at using high dose alefacept would 
be to use multiple centers to provide a greater range of results in order to have a larger sample 
size.  Comparing a sample of 8 to 166 seems in effective.  The other control trials used 
multicenters to conduct their research and collect data.  Also, high dose alefacept should be 
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tested against a placebo and not another control group that does consist partially of the 
experimental dose in it.  This way all three trials are being tested against a control and would 
make results each variable more consistent. 
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